Question to the Department of Health and Social Care:

To ask Her Majesty's Government what steps they are taking to address staff capacity issues within the Medicines and Healthcare products Regulatory Agency to ensure that patients get treatments in a timely manner.

The Medicines and Healthcare products Regulatory Agency (MHRA) is moving to a focused and integrated organisational model to improve the outcomes it delivers for patients and the public. The MHRA has designed its proposed structure around the lifecycle of a product: science; research and innovation; healthcare; quality and access; and safety and surveillance. This will refocus its resources to ensure that new treatments are licensed and delivered more quickly. While the MHRA will be a smaller organisation, it will retain and increase its scientific and regulatory capabilities.